Australian diagnostics firm HealthLinx this week released results from the first stage of an ongoing 1,150-subject study investigating the performance of OvPlex, its protein biomarker-based ovarian cancer diagnostic.

According to an initial analysis of the first-stage data performed by Emphron Informatics, the OvPlex test was able to distinguish between stage I and II epithelial ovarian cancer patients and controls with 92 percent accuracy, compared to 80 percent accuracy for CA125, currently the standard protein biomarker diagnostic for ovarian cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.